Summary of findings 1. Summary of findings.
| Radiotherapy plus chemotherapy compared withradiotherapy for early stage cervical cancer | |||||
|
Patient or population: patients with early stage cervical cancer Settings: inpatient or outpatient Intervention: radiotherapy plus chemotherapy Comparison: radiotherapy | |||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | |
| Assumed risk | Corresponding risk | ||||
| Radiotherapy | Radiotherapy pluschemotherapy | ||||
| Death from all causes Follow‐up: 42 months | 310 per 10001 | 188 per 1000 (125 to 276) | HR 0.56 (0.36 to 0.87) | 297 (2 studies) | ⊕⊕⊕⊝ moderate2 |
| Disease progression Follow‐up: 42 months | 353 per 10001 | 185 per 1000 (122 to 275) | HR 0.47 (0.3 to 0.74) | 297 (2 studies) | ⊕⊕⊕⊝ moderate2 |
| Grade 4 toxicity3 | 26 per 1000 | 182 per 1000 (72 to 454) | RR 6.26 (2.50 to 15.67) | 321 (3 studies) | ⊕⊕⊕⊝ moderate2 |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio; | |||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | |||||
1 Due to censoring and differing levels of follow‐up combined figures from the two studies were not used. Peters 2000 explicitly reported four‐year survival rate and carried substantially more weight in the meta‐analysis, therefore we used the numbers from this trial.
2 Trial of Peters 2000 was reported early because interim analysis showed benefit of radiotherapy plus chemotherapy.
3 The results from radiotherapy plus chemotherapy and chemotherapy plus radiotherapy followed by consolidation chemotherapy in the Sun 2015 trial were analysed together for the outcome of grade 4 toxicity.